Merck KGaA Agrees To Acquire Silence Therapeutics For $20 Per ADS In Cash

Merck KGaA has agreed to acquire Silence Therapeutics plc for $20 per ADS in cash, equating to $6.6667 per ordinary share. This acquisition values Silence Therapeutics at approximately $1.1 billion in enterprise value and $1.3 billion in equity value, representing an 82% premium over its 30-day average stock price of $10.99 prior to the announcement. The transaction is contingent upon customary closing conditions.